子宫内膜样成分不改变子宫浆液性癌的临床病理特征与生存
基于GOG-0210前瞻性队列中934例子宫浆液性癌患者,6名妇科病理专家按H&E形态将其分为纯浆液性(SER,n=663)、浆液-子宫内膜样混合(SER-EM-M,n=138)和浆液与子宫内膜样难鉴别(SER-EM-I,n=133)三组。多因素回归显示浆液性亚型并不显著预测生存,混合或难鉴别形态者的生存与纯浆液性癌相同。
要点
- 浆液-子宫内膜样混合或难鉴别形态者的生存与纯浆液性癌无差异。
- SER-EM-M患者更年轻(p=0.0001)且淋巴结受累更少(p=0.0287)。
- 多因素回归中浆液性亚型不显著预测无进展生存和总生存。
核心结论
- 在浆液性癌中,存在子宫内膜样成分或形态难鉴别并不改变临床病理特征或生存,浆液性亚型在多因素回归中不显著预测生存。
研究设计与样本
- 妇科肿瘤组(GOG/NRG)研究GOG-8032,自GOG-0210较大入组人群中前瞻性识别934例子宫浆液性癌患者。
- 由6名妇科病理专家按H&E形态分类:纯浆液性(SER,n=663)、浆液-子宫内膜样混合(SER-EM-M,n=138)、浆液与子宫内膜样难鉴别(SER-EM-I,n=133)。
- 分析GOG-0210的随访数据;试验注册号NCT00340808。
主要发现
- 各亚组在BMI、种族、民族、淋巴血管浸润、宫颈侵犯、卵巢受累、腹膜受累、大网膜受累、FIGO分期或计划辅助治疗上无差异。
- SER-EM-M患者更年轻(p=0.0001),淋巴结受累更少(p=0.0287)。
- SER患者肌层浸润更少(p=0.0002),附件受累更多(p=0.0108)。
- 单因素分析中,年龄、浆液性亚型、种族和FIGO分期组成部分均预测无进展生存和总生存。
- 多因素回归中,浆液性亚型(SER、SER-EM-M或SER-EM-I)不显著预测生存。
关键数值与推荐
- 浆液性亚型多因素回归未显著预测生存(原文未报告具体风险比与P值)。
- SER-EM-M与淋巴结受累关联p=0.0287,SER与肌层浸润关联p=0.0002,SER与附件受累关联p=0.0108。
临床怎么用
- 形态学上出现子宫内膜样成分或难以区分浆液与子宫内膜样时,不应据此外推为预后更优。
- 浆液性癌的预后判断应结合年龄、种族和FIGO分期等已证实预测因素。
局限性
- 亚型分类基于H&E形态,未报告分子分型数据。
- 为GOG-0210入组人群中的前瞻性识别队列,非随机干预研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: While most cases of endometrial cancer can readily be classified as pure endometrioid, pure serous, or another type, others show an apparent mixture of serous and endometrioid components, or indeterminate serous versus endometrioid features. Since serous histology carries a worse prognosis than endometrioid, Gynecologic Oncology Group protocol GOG-8032 was established to examine whether the presence of a non-serous component is a favorable feature in an otherwise serous cancer. METHODS: 934 women with serous cancer were prospectively identified among a larger group enrolled in GOG-0210. Six expert gynecologic pathologists classified each case as pure serous (SER, n=663), mixed serous and endometrioid (SER-EM-M, n=138), or indeterminate serous v. endometrioid (SER-EM-I, n=133) by H&E morphology. Follow-up data from GOG-0210 were analyzed. RESULTS: The subgroups did not differ on BMI, race, ethnicity, lymphovascular invasion, cervical invasion, ovary involvement, peritoneal involvement, omental involvement, FIGO stage, or planned adjuvant treatment. SER-EM-M patients were younger (p=0.0001) and less likely to have nodal involvement (p=0.0287). SER patients were less likely to have myoinvasion (p=0.0002), and more likely to have adnexal involvement (p=0.0108). On univariate analysis, age, serous subtype, race, and components of FIGO staging predicted both progression-free and overall survival. On multiple regression, however, serous subtype (SER, SER-EM-M, or SER-EM-I) did not significantly predict survival. CONCLUSIONS: There were few clinicopathologic differences between cases classified as SER, SER-EM-M, and SER-EM-I. Cases with a mixture of serous and endometrioid morphology, as well as cases with morphology indeterminate for serous v. endometrioid type, had the same survival as pure serous cases. NCT#: NCT00340808.
引用
- Hagemann IS, Deng W, Zaino RJ, et al. The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women. Gynecol Oncol. 2021. PMID: 33423806. doi:10.1016/j.ygyno.2020.12.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。